Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Status:
Active, not recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
Venetoclax and ibrutinib have complementary activity in clearing the disease across
anatomical compartments. By combining ibrutinib with venetoclax, cells can be mobilized from
tissues into the bloodstream by ibrutinib and killed in the blood by venetoclax.
Consistently, the venetoclax-ibrutinib combination can achieve undetectable minimal residual
disease (MRD-neg) in a sizable proportion of patients. Gentle debulking obtained with a
lead-in phase of ibrutinib monotherapy may allow starting venetoclax when the disease has
been reshaped in a size that fits for low-risk of tumor lysis syndrome (TLS), a rare adverse
event (AE) of venetoclax. MRD-guided treatment duration may allow patients achieving a
negative status to gain drug-free intervals and less medicalization, and may avoid all the
potential, and not yet completely known implications of continuous therapy on long-term
safety, drug interactions, quality of life, compliance to treatment, and economic
sustainability.